Davis Polk advised AC Immune SA in connection with its $117.5 million U.S. follow-on public offering. AC Immune sold 8,500,000 of its newly issued common shares and subscription rights offerings pursuant to a first subscription rights offering and an underwritten registered public offering, which included 1,108,695 common shares from the full exercise of the underwriters’ over-allotment option to purchase additional shares. Subsequently, AC Immune sold 1,500,000 of its newly issued common shares pursuant to a second subscription rights offering. The common shares are listed on the NASDAQ Global Market under the symbol “ACIU.”

Based in Lausanne, Switzerland, AC Immune is a clinical stage Swiss-based biopharmaceutical company focused on neurodegenerative diseases with four product candidates in clinical trials. AC Immune designs, discovers and develops therapeutic and diagnostic products intended to prevent and modify diseases caused by misfolding proteins.

The Davis Polk corporate team included partner Derek Dostal and associates Martin Oberst, Dan Gibbons and Young-Min Cho. The intellectual property and technology team included partner David R. Bauer and associates Bonnie Chen and Mikaela Dealissia. The tax team included partner Michael Mollerus and associate Tomislava Dragicevic. All members of the Davis Polk team are based in the New York office.

Copy link to share post